TSE:4587Biotechs
PeptiDream (TSE:4587) Narrows Q4 Loss To ¥531.7m Testing Bullish Profitability Narrative
PeptiDream (TSE:4587) has wrapped up FY 2025 with fourth quarter revenue of ¥5,663.6 million and a basic EPS loss of ¥4.11. Trailing twelve month figures show revenue of ¥18,521 million and a basic EPS loss of ¥28.99, underlining that the business is still operating at a loss. The company has seen quarterly revenue move from ¥5,071.7 million in Q4 FY 2024 to ¥5,663.6 million in Q4 FY 2025, alongside quarterly basic EPS moving from a loss of ¥20.11 to a loss of ¥4.11, as investors weigh that...